Jsb Market Research: Global and Usa Cancer Biomarker Market to 2018

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 280 tables & figures over 232 pages. The oncology biomarker (globaland USA) market is presented as follows:

By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD, FOUNDATION MEDICINE, GENOMIC HEALTH)
By Geography (Global, US)

By Sub-market (Global Biomarker Market, Cancer Biomarker Market, Global Cancer Profiling Technology Market )

A wealth of financial data & business strategy information is provided including:

Up-to-date company financials, sales & revenue figures
Revenue and market forecasts up to 2018
Business model strategies for diagnostic, pharmaceutical and biotechnology companies
Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
Comprehensive account of company product financials, portfolios & kits
SWOT, Economic & Regulatory Environment specifics include:
Key strengths, weaknesses and threats influencing leading player position within the market
Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
Top fastest growing market segments and emerging opportunities
Top pharmaceutical companies within the cancer biomarker market
Comprehensive product portfolios, R&D activity and pipeline therapeutics
M&A activity and future strategies of top companies
Approved biomarker companion diagnostic tests
High demand and Unmet Need Enhances the Global Biomarker Market
FDA Support Increases Biomarker Development
More Streamlined Clinical Trials
Significant Growth of High-Impact Oncogenic Biomarker Research
Advancements in Discovery Technologies
Challenges of the Oncogenic Biomarker Market
Variability of Biomarkers within Different Cancer Subtypes
Integration of Genomics and Biomarker Diagnostics into the Healthcare...